Headquartered in Beijing, CANbridge is a global bio-pharmaceutical company with a mission to accelerate development and commercialization of life-changing specialty healthcare products in China and North Asia.
CANbridge’s strategy is to bridge the world’s richest product pipeline to one of the world’s fastest growing markets through its highly efficient commercial platform.
CANbridge’s founder and CEO, James Xue, PhD, MBA, is a former Genzyme executive and the founding general manager of Genzyme China.
CANbridge has assembled a world class management and advisory team with the capability to select, acquire, develop and deliver promising therapeutics and diagnostics to address the severely underserved medical needs of patients in China and Asia.
We are a leading bio-pharmaceutical company focusing on delivering life-changing therapeutics and diagnostics to address the unmet medical needs of Chinese and Asian patients.
We seek to deliver life-changing therapeutics and diagnostics that will contribute to society and yield a good return for our investors.
In order to promote and boost the combination of finance and bio-technology and promote the development of the bio-medicine industry in Beijing area, support the mid-sized and small-sized initial enterprises focusing on bio-medicine. Beijing SME Service Center worked with Beijing Yangfang Shengli Investment Management Co., Ltd, Ningxia Zhong’e Industry Investment Fund Management Enterprise (limited partnership), Tibet Dongrun Investment Holding Co., Ltd, Beijing Chongde Yingsheng Investment Management Co., Ltd on June 5, 2015 to set up Beijing Chongde Yingsheng Pioneering Investment Co., Ltd (“Chongde Yingsheng” or “Chongde Yingsheng Fund” for short), with the registered.
Beijing Longpan Investment Management Consultation Center (general partnership) was established in 2011. The professional investment field of the company is biological medicine industry. In terms of the fund, it will pay special attention to the bio pharm, chemical pharm, characteristic raw materials and advanced treatment and diagnosis equipment.
Qiming strives to be the investor of choice for top entrepreneurs in China. Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development. With access to our partners’ experience and global network as well as our excellent industry background, we spare no efforts in helping our entrepreneurs and their companies succeed!
TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.
Hangzhou Tigermed Consulting Co., Ltd is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Established in December 2000, WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services throughout the drug R&D process.
Zhongling Yanyuan Bio-medicine Pioneering Fund is one of the first batch of sharing pioneering investment fund of the new industry venture and investment plan in our country. The state and Beijing Municipal Government provide guidance in capital and policy. By combining the professional investment ability and resource integration ability of Zhongling Yanyuan Bio-medicine Pioneering Fund, they jointly support the bio-medicine enterprise.
YuanMing Capital is a healthcare specialty fund focusing on China-US cross border investments with offices in Beijing and New York City. The investment team has rich industry experience and a successful investment track record. The fund invests in therapeutics, medical devices, diagnostics as well as healthcare service companies based in US and/or China. YuanMing Capital seek to bring capital and strategic resources to the future leaders of the industry.
PARTNERSHIP & RECONGNITIONMORE
Suite 301, 3F, Timeloit, No.17 RongChuang Road, Chaoyang District, Beijing, China
Suite 708, Huawen International Mansion, No.999, Zhongshan West Road, Changning District, Shanghai
4F, One BroadWay, Cambridge, MA 02142